Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

529
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
529
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

962
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
962
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

268
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
268
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

318
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
318

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing equity within the promotions dossier evaluation-Strategies to mitigate biases.

Frontiers in public health·2026
Same author

Strategies For Enhancing Equity, Diversity, and Inclusion in Medical School Admissions-A Canadian Medical School's Journey.

Frontiers in public health·2022
Same author

Bilateral adrenal histoplasmosis manifesting as primary adrenal insufficiency.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2019
Same author

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018.

The Canadian journal of cardiology·2018
Same author

Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.

World journal of gastroenterology·2017
Same author

Management strategies in patients with statin-associated muscle symptoms: What is the best strategy?

Journal of clinical lipidology·2016

Related Experiment Video

Updated: Mar 3, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.8K

Management Strategies for Statin-Associated Muscle Symptoms: How Useful Is Same-Statin Rechallenge?

Emily T Brennan1, Tisha R Joy1

  • 1Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

The Canadian Journal of Cardiology
|April 29, 2017
PubMed
Summary

Most patients with statin-associated muscle symptoms (SAMS) can tolerate statin therapy. Same-statin rechallenge is a well-tolerated and effective strategy for managing SAMS and lowering LDL-C levels.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

4.4K

Related Experiment Videos

Last Updated: Mar 3, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.8K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

4.4K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Therapeutics

Background:

  • Statin-associated muscle symptoms (SAMS) are a frequent clinical challenge.
  • Limited data exists on the efficacy and tolerability of same-statin rechallenge compared to other strategies for SAMS management.

Purpose of the Study:

  • To evaluate the tolerability and efficacy of same-statin rechallenge versus statin switch and nonstatin therapy in patients with SAMS.
  • To compare the percentage change in low-density lipoprotein cholesterol (LDL-C) and achievement of LDL-C targets among the three strategies.

Main Methods:

  • Retrospective analysis of 118 patients referred for SAMS management.
  • Patients were categorized into same-statin rechallenge, statin switch, or nonstatin therapy groups.
  • Tolerability was defined as remaining on the assigned strategy at last follow-up.

Main Results:

  • Most patients (67%) tolerated statin therapy after intervention.
  • Tolerability was similar across strategies (71% same-statin rechallenge, 53% statin switch, 57% nonstatin).
  • Same-statin rechallenge and statin switch groups showed significantly greater LDL-C reduction compared to nonstatin therapy (-38.8% and -36.4% vs -17.3%).
  • A higher proportion of patients on same-statin rechallenge achieved their LDL-C target (50%) compared to nonstatin therapy (15%).

Conclusions:

  • The majority of patients with a history of SAMS can successfully tolerate statin therapy.
  • Same-statin rechallenge demonstrates high tolerability and efficacy in managing SAMS and improving lipid profiles.
  • Increased utilization of same-statin rechallenge may be warranted for patients experiencing SAMS.